Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors
- PMID: 9307194
Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors
Abstract
Background: It is often assumed that a cerebral lesion that is nonenhancing on a magnetic resonance imaging study with gadolinium contrast is a low grade tumor. Some physicians recommend observation rather than biopsy for such lesions.
Methods: The authors prospectively evaluated the incidence of anaplastic tumor histology in a consecutive series of patients who presented to a neuro-oncology service with a nonenhancing mass of the cerebral hemisphere.
Results: During a 5-month period, the authors evaluated 31 patients who had a nonenhancing lesion in the cerebral hemisphere on initial magnetic resonance images. Thirty patients underwent stereotactic biopsy (27%) or open resection (73%). The median patient age was 36 years (range, 6-63 years). There was no mortality or permanent neurologic morbidity from surgery. Twenty-eight patients had pathologic confirmation of diagnosis while their lesions were still nonenhancing. Of these patients, 9 (32%) had Grade 3 lesions (anaplastic astrocytoma or oligoastrocytoma), 13 (43%) had Grade 2 lesions (astrocytoma, oligodendroglioma, or oligoastrocytoma), and 2 (7%) had Grade 1 lesions (dysembryoplastic neuroepithelial tumors). Two additional patients (ages 33 and 59 years) who developed enhancement within their lesions during preoperative periods of observation had glioblastomas at surgery. Logistic regression was used to relate patient age to the risk of anaplasia in a nonenhancing cerebral mass lesion. Older age predicted a significantly higher risk of anaplasia (P = 0.025). The model predicted that nonenhancing cerebral masses in patients older than 44 years were more likely to be anaplastic tumors than low grade tumors. There was no "safe" age below which low grade histology could be confidently assumed.
Conclusions: Magnetic resonance-nonenhancing cerebral lesions may be histologically anaplastic, even in young patients. The risk of anaplasia in magnetic resonance-nonenhancing lesions increases significantly with patient age.
Similar articles
-
Supratentorial gangliogliomas: histopathologic grading and tumor recurrence in 184 patients with a median follow-up of 8 years.Cancer. 2004 Jul 1;101(1):146-55. doi: 10.1002/cncr.20332. Cancer. 2004. PMID: 15222000
-
Low-grade glioma on stereotactic biopsy: how often is the diagnosis accurate?Minim Invasive Neurosurg. 2008 Oct;51(5):275-9. doi: 10.1055/s-0028-1082322. Epub 2008 Oct 14. Minim Invasive Neurosurg. 2008. PMID: 18855292
-
[Significance of stereotactic biopsy for the management of WHO grade II supratentorial glioma].Nervenarzt. 2003 Apr;74(4):350-4. doi: 10.1007/s00115-003-1487-4. Nervenarzt. 2003. PMID: 12707704 German.
-
Supratentorial high grade astroblastoma: report of two cases and review of the literature.Turk Neurosurg. 2009 Apr;19(2):149-52. Turk Neurosurg. 2009. PMID: 19431125 Review.
-
[A multicentric glioma exhibiting three supratentorial lesions].No Shinkei Geka. 1994 Jan;22(1):81-4. No Shinkei Geka. 1994. PMID: 8295708 Review. Japanese.
Cited by
-
Gliomatosis cerebri: clinical characteristics, management, and outcomes.J Neurooncol. 2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. J Neurooncol. 2013. PMID: 23341100 Free PMC article. Clinical Trial.
-
Diffusion MRI in the early diagnosis of malignant glioma.J Neurooncol. 2007 Apr;82(2):221-5. doi: 10.1007/s11060-006-9273-3. Epub 2006 Oct 7. J Neurooncol. 2007. PMID: 17029014
-
Prediction of IDH Status Through MRI Features and Enlightened Reflection on the Delineation of Target Volume in Low-Grade Gliomas.Technol Cancer Res Treat. 2019 Jan 1;18:1533033819877167. doi: 10.1177/1533033819877167. Technol Cancer Res Treat. 2019. PMID: 31564237 Free PMC article.
-
Molecular imaging of glioblastoma multiforme using anti-insulin-like growth factor-binding protein-7 single-domain antibodies.Br J Cancer. 2010 Nov 9;103(10):1606-16. doi: 10.1038/sj.bjc.6605937. Epub 2010 Oct 19. Br J Cancer. 2010. PMID: 20959824 Free PMC article.
-
Personalized treatment strategies in glioblastoma: MGMT promoter methylation status.Onco Targets Ther. 2013 Sep 27;6:1363-72. doi: 10.2147/OTT.S50208. Onco Targets Ther. 2013. PMID: 24109190 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical